---
document_datetime: 2026-01-19 16:37:28
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/opuviz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: opuviz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.9624696
conversion_datetime: 2026-01-20 20:39:10.786357
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Opuviz

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 02/12/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000306620   |
|---------------------|

<div style=\"page-break-after: always\"></div>

|                                       | process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |                        |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|
| Variation type II / EMA/VR/0000280586 | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.d Site which requires an initial or product specific inspection - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Minor change in the manufacturing process of a sterile finished product after the primary packaging step - Accepted B.II.e.1.b Change in type of container or addition of a new container - B.II.e.1.b.2 Sterile medicinal products and biological/ immunological medicinal products - Accepted | 27/11/2025 |     | SmPC, Labelling and PL |
| Variation type IB / EMA/VR/0000301944 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20/10/2025 | N/A |                        |

<div style=\"page-break-after: always\"></div>

|                                       | substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted                                                                       |            |     |             |                                                                                                                                                                                                                                                   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000302007 | B.II.c.2 Change in test procedure for an excipient - B.II.c.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                              | 17/10/2025 | N/A |             |                                                                                                                                                                                                                                                   |
| Variation type IB / EMA/VR/0000281508 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted | 14/08/2025 | N/A |             |                                                                                                                                                                                                                                                   |
| Article 61(3) / EMA/N/0000281956      | - Notification acc. Article 61(3) - Accepted Update of the package leaflet to delete the list of contact details of local representatives                                                                                                                                                                           | 16/07/2025 |     | PL          |                                                                                                                                                                                                                                                   |
| Variation type IB / EMA/VR/0000265733 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a                                                                                               | 14/05/2025 |     | SmPC and PL | To update section 4.8 of the SmPC in order to add 'scleritis' to the list of adverse drug reaction (ADRs), following assessment of the same change for the reference product Eylea. The PL is updated accordingly. Additionally, the MAH took the |

<div style=\"page-break-after: always\"></div>

|                                       | Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update section 4.8 of the SmPC in order to add 'scleritis' to the list of adverse drug reaction (ADRs) with frequency of '0.2 cases per 1 milion injections' based on pharmacovigilance data, following assessment of the same change for the reference product Eylea. The PL is updated accordingly. Additionally, the MAH took the opportunity to update the SmPC and PL to add warnings for polysorbate 20 in line with the EC Excipient Guideline.   |            | opportunity to update the SmPC and PL to add warnings for polysorbate 20 in line with the EC Excipient Guideline.   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000254853 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.c The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - Accepted                                                                                                                                                                             | 08/05/2025 |                                                                                                                     |